TY - JOUR
T1 - Whole exome sequencing of rare aggressive breast cancer histologies
AU - Dieci, Maria Vittoria
AU - Smutná, Veronika
AU - Scott, Véronique
AU - Yin, Guangliang
AU - Xu, Ran
AU - Vielh, Philippe
AU - Mathieu, Marie Christine
AU - Vicier, Cécile
AU - Laporte, Melanie
AU - Drusch, Francoise
AU - Guarneri, Valentina
AU - Conte, Pierfranco
AU - Delaloge, Suzette
AU - Lacroix, Ludovic
AU - Fromigué, Olivia
AU - André, Fabrice
AU - Lefebvre, Celine
N1 - Publisher Copyright:
© 2016, Springer Science+Business Media New York.
PY - 2016/2/1
Y1 - 2016/2/1
N2 - Little is known about mutational landscape of rare breast cancer (BC) subtypes. The aim of the study was to apply next generation sequencing to three different subtypes of rare BCs in order to identify new genes related to cancer progression. We performed whole exome and targeted sequencing of 29 micropapillary, 23 metaplastic, and 27 pleomorphic lobular BCs. Micropapillary BCs exhibit a profile comparable to common BCs: PIK3CA, TP53, GATA3, and MAP2K4 were the most frequently mutated genes. Metaplastic BCs presented a high frequency of TP53 (78 %) and PIK3CA (48 %) mutations and were recurrently mutated on KDM6A (13 %), a gene involved in histone demethylation. Pleomorphic lobular carcinoma exhibited high mutation rate of PIK3CA (30 %), TP53 (22 %), and CDH1 (41 %) and also presented mutations in PYGM, a gene involved in glycogen metabolism, in 8 out of 27 samples (30 %). Further analyses of publicly available datasets showed that PYGM is dramatically underexpressed in common cancers as compared to normal tissues and that low expression in tumors is correlated with poor relapse-free survival. Immunohistochemical staining on formalin-fixed paraffin-embedded tissues available in our cohort of patients confirmed higher PYGM expression in normal breast tissue compared to equivalent tumoral zone. Next generation sequencing methods applied on rare cancer subtypes can serve as a useful tool in order to uncover new potential therapeutic targets. Sequencing of pleomorphic lobular carcinoma identified a high rate of alterations in PYGM. These findings emphasize the role of glycogen metabolism in cancer progression.
AB - Little is known about mutational landscape of rare breast cancer (BC) subtypes. The aim of the study was to apply next generation sequencing to three different subtypes of rare BCs in order to identify new genes related to cancer progression. We performed whole exome and targeted sequencing of 29 micropapillary, 23 metaplastic, and 27 pleomorphic lobular BCs. Micropapillary BCs exhibit a profile comparable to common BCs: PIK3CA, TP53, GATA3, and MAP2K4 were the most frequently mutated genes. Metaplastic BCs presented a high frequency of TP53 (78 %) and PIK3CA (48 %) mutations and were recurrently mutated on KDM6A (13 %), a gene involved in histone demethylation. Pleomorphic lobular carcinoma exhibited high mutation rate of PIK3CA (30 %), TP53 (22 %), and CDH1 (41 %) and also presented mutations in PYGM, a gene involved in glycogen metabolism, in 8 out of 27 samples (30 %). Further analyses of publicly available datasets showed that PYGM is dramatically underexpressed in common cancers as compared to normal tissues and that low expression in tumors is correlated with poor relapse-free survival. Immunohistochemical staining on formalin-fixed paraffin-embedded tissues available in our cohort of patients confirmed higher PYGM expression in normal breast tissue compared to equivalent tumoral zone. Next generation sequencing methods applied on rare cancer subtypes can serve as a useful tool in order to uncover new potential therapeutic targets. Sequencing of pleomorphic lobular carcinoma identified a high rate of alterations in PYGM. These findings emphasize the role of glycogen metabolism in cancer progression.
KW - Glycogen metabolism
KW - Metaplastic breast cancer
KW - Micropapillary breast cancer
KW - PYGM
KW - Pleomorphic lobular breast cancer
KW - Sequencing
UR - http://www.scopus.com/inward/record.url?scp=84961160009&partnerID=8YFLogxK
U2 - 10.1007/s10549-016-3718-y
DO - 10.1007/s10549-016-3718-y
M3 - Article
C2 - 26907767
AN - SCOPUS:84961160009
SN - 0167-6806
VL - 156
SP - 21
EP - 32
JO - Breast Cancer Research and Treatment
JF - Breast Cancer Research and Treatment
IS - 1
ER -